General Information

Age Group

Adults

Status

Active

Protocol Number

NCT06958328

Background Information

This study is being done to answer the following question:  

Can the addition of a high dose of radiation therapy extend life or improve quality of life?  

We are doing this study because we want to find out if this approach is better or worse than the usual approach for locally advanced pancreatic cancer.  The usual approach is defined as care most people get for locally advanced pancreatic cancer. 

For more information, please visit https://clinicaltrials.gov/study/NCT06958328

Offered At

8081 Innovation Park Drive Fairfax, VA 22031
3600 Joseph Siewick Dr, Fairfax, VA 22033
3300 Gallows Rd, Falls Church, VA 22042
44045 Riverside Pkwy, Leesburg, VA 20176
Principal Investigator

Tobias Chapman, MD

Ineligibility Information

  • Must have received 4-6 months of active chemotherapy with FOLFIRINOX or NALIRIFOX or gemcitabine/Nab-Paclitaxel
  • Must have proven diagnosis of pancreatic ductal adenocarcinoma
    • locally advanced unresectable disease
    • must have baseline pre-chemotherapy scans for staging
  • Age 18 years or older
  • Performance status ECOG 0-2
  • Baseline CA19-9 with a normal bilirubin level
  • No active duodenal or gastric ulcers
  • no direct tumor invasion of the bowel or stomach
  • re-staging scans scans showing at least stable disease (no progression)
  • Not pregnant and not nursing
  • no cardiac condition that was the primary reason for hospitalization in the last 6 months
  • New York Heart Association Functional Classification II or better
  • HIV infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible